http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
김창세,조경욱 순천향대학교 1989 논문집 Vol.12 No.1
The measurement of HbA1c was found satisfactorily. 1. Absoption spectrum of hemolysate was at 415nm. 2. The chromatography was performed such as following conditions: buffer gradient and step elution time was followed on Table 1, resin Dowex 50, flow rate 1 ml/min, and 2 ml/tube. From the above results the blood HbA1c could be satisfactorily measured by means of chromatographic method, author' modified, without interference of HbF.
조경욱,김예지,박경민,김선옥,김영학,강지은,심태선,홍석찬 대한결핵 및 호흡기학회 2016 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.121 No.-
Backgrounds: We investigated whether the incidence of cardiovascular disease is (1) higher during the course of active tuberculosis, and (2) related to pyrazinamide use. Methods: The population-based retrospective cohort study was conducted in active tuberculosis patients treated with the standard regimen and identified using the Korean Health Insurance Review and Assessment Service database from January 1, 2010 to December 31, 2014. The primary outcome was hospitalization for cardiovascular disease combined with cerebrovascular disease and acute myocardial infarction. The standardized incidence ratio (SIR) was calculated by comparing the active tuberculosis patients with the general population stratified by age and sex. The adjusted hazard ratio (HR) among tuberculosis patients was evaluated according to the treatment phase. Results: A total of 69023 active tuberculosis patients who received standard antituberculosis treatment were identified through eligibility screening. The incidence of cardiovascular disease in these patients was 7·79 per 1000 person-years. SIR was significantly higher in these patients than in the age- and sex-stratified population (SIR, 2.89; 95% CI 2.58-3.23). After covariate adjustment, the risk of cardiovascular disease development was higher during the pyrazinamide-containing intensive phase than during the continuation phase (adjusted HR 2.20, 95% CI 1.33-3.62). Conclusion: These results suggest that active tuberculosis can be considered a pertinent risk factor for cardiovascular disease, particularly in the intensive phase.
조경욱,이소연,강미란,성흥섭,김미나,심태선 대한결핵 및 호흡기학회 2016 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.121 No.-
Backgrounds: We investigated (1) the frequency and common types of disputed rpoB mutations; and (2) the treatment outcomes for patients with M.tb isolates containing these mutations. In addition, we sought to develop a rapid molecular test to detect the disputed rpoB mutations. Methods: The patient data was derived from Asan Medical Center. We also identified M.tb strains from which rpoB sequencing revealed disputed mutations at the International Tuberculosis Research Center (ITRC) to investigate the most common types. A rapid molecular test was developed with YD Diagnostics. Results: Of the 130 patients shown as rifampin resistant on the MTBDRplus assay, the results of the DST indicated that 15 patients were rifampin susceptible. Among these 15 patients, the rpoB sequencing from nine patients revealed disputed rpoB mutations. Thus, the frequency of disputed rpoB mutations was at least 6.9% (9/130) of cases with rifampin-resistant on the MTBDRplus assay. All nine patients received individualized treatment regimens, with the majority exhibiting favorable outcomes. The sequencing results from our hospital and the ITRC revealed that the common types of disputed mutations in order of frequency are as follows: CTG511CCG; GAC516TAC; CTG533CCG; CAC526CTC; and CAC526AAC. Based on these results, we have developed a rapid molecular test by supplementing the probes to the MolecuTech REBA MTB-MDR kit (YD Diagnostics, South Korea). Conclusion: Disputed rpoB mutations are not quite rare in South Korea. The rapid molecular test was successfully developed after identifying common types.
Preventing the Transmission of Tuberculosis in Health Care Settings: Administrative Control
조경욱 대한결핵및호흡기학회 2017 Tuberculosis and Respiratory Diseases Vol.80 No.1
It is well established that health care workers (HCWs) have a considerably higher risk of occupationally acquired tuberculosis (TB). To reduce the transmission of TB to HCWs and patients, TB infection control programs should be implemented in health care settings. The first and most important level of all protection and control programs is administrative control. Its goals are to prevent HCWs, other staff, and patients from being exposed to TB, and to reduce the transmission of infection by ensuring rapid diagnosis and treatment of affected individuals. Administrative control measures recommended by the United States Centers for Disease Control and Prevention and the World Health Organization include prompt identification of people with TB symptoms, isolation of infectious patients, control of the spread of the pathogen, and minimization of time spent in health care facilities. Another key component of measures undertaken is the baseline and serial screening for latent TB infection in HCWs who are at risk of exposure to TB. Although the interferon-gamma release assay has some advantages over the tuberculin skin test, the former has serious limitations, mostly due to its high conversion rate.
조경욱,김미혜,김예지,이현경,김현국,전두수,류지원,박혜경,목정하,김주상,허은영,최상봉,임재준,심태선 대한결핵 및 호흡기학회 2018 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.126 No.-
Background: We aimed to determine the feasibility of discontinuing ethambutol (EMB) before the end of intensive phase treatment based on the result of GenoType MTBDRplus assay in patients with pulmonary tuberculosis (TB). Methods: This prospective, multicenter non-inferiority randomized trial was conducted at 12 referral centers in South Korea in patients with pulmonary TB who received the standard four-drug regimen. In the MTBDRplus group, EMB was discontinued immediately after confirmation that the M. tuberculosis isolate was susceptible to isoniazid and rifampin according to the MTBDRplus assay. In the Guideline group, the timing of EMB discontinuation was determined using results of the phenotypic drug susceptibility test based on the Korean TB guidelines. The primary outcome was treatment success. Secondary outcomes included the 1-year rates of recurrence and adverse events. Results: Of the 600 enrolled patients, 507 were randomized, with 419 remaining for primary outcome analysis (MTBDRplus group, 202; Guideline group, 217). Treatment success rates were 94.6% (191/202) and 94.5% (205/217), respectively (P=0.970), with a relative risk of 1.00 (95% CI 0.95-1.06). For patients followed up for 1 year after treatment, the 1-year recurrence rate did not differ between the two groups (1.1% [2/183] vs. 0.5% [1/199], respectively [P=0.609]). We found no significant between-group differences of adverse drug reactions. Conclusion: Early discontinuation of EMB during the intensive phase based on results of the MTBDRplus assay did not affect treatment outcome in pulmonary TB.